JP2017512833A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512833A5 JP2017512833A5 JP2017501110A JP2017501110A JP2017512833A5 JP 2017512833 A5 JP2017512833 A5 JP 2017512833A5 JP 2017501110 A JP2017501110 A JP 2017501110A JP 2017501110 A JP2017501110 A JP 2017501110A JP 2017512833 A5 JP2017512833 A5 JP 2017512833A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocyclyl
- alkyl
- aralkyl
- alkynyl
- alkenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000623 heterocyclic group Chemical group 0.000 claims 52
- 125000000217 alkyl group Chemical group 0.000 claims 41
- 125000003710 aryl alkyl group Chemical group 0.000 claims 39
- 125000001072 heteroaryl group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 38
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 36
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 36
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- 150000001875 compounds Chemical class 0.000 claims 20
- 125000005843 halogen group Chemical group 0.000 claims 17
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000001424 substituent group Chemical group 0.000 claims 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 14
- 230000000155 isotopic effect Effects 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000012453 solvate Substances 0.000 claims 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 11
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 9
- -1 C 7-15 aralkylene Chemical group 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 8
- 229940002612 prodrug Drugs 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000000732 arylene group Chemical group 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000005549 heteroarylene group Chemical group 0.000 claims 6
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- GBXQPDCOMJJCMJ-UHFFFAOYSA-M trimethyl-[6-(trimethylazaniumyl)hexyl]azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCCCCC[N+](C)(C)C GBXQPDCOMJJCMJ-UHFFFAOYSA-M 0.000 claims 4
- 125000006586 (C3-C10) cycloalkylene group Chemical group 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- 102000001301 EGF receptor Human genes 0.000 claims 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 0 CC*c(c(O)c1nc(*C(**)=N)[n](CC2CC(*)C2)c1c1*)c1[U]* Chemical compound CC*c(c(O)c1nc(*C(**)=N)[n](CC2CC(*)C2)c1c1*)c1[U]* 0.000 description 7
- CWVIXYOYDKCWSV-UHFFFAOYSA-N CC(CC1)CCS1(=O)=[O]I Chemical compound CC(CC1)CCS1(=O)=[O]I CWVIXYOYDKCWSV-UHFFFAOYSA-N 0.000 description 1
- AOCWQPKHSMJWPL-UHFFFAOYSA-N CC(CCN1)C1=O Chemical compound CC(CCN1)C1=O AOCWQPKHSMJWPL-UHFFFAOYSA-N 0.000 description 1
- CODIMGJCYJUGOB-XMMPIXPASA-N CC(N(CC1)CCC1Nc1cccc2c1[n]([C@H](CCCC1)CN1C(C=C)=O)c(NC(c1cc(C)ncc1)=O)n2)=O Chemical compound CC(N(CC1)CCC1Nc1cccc2c1[n]([C@H](CCCC1)CN1C(C=C)=O)c(NC(c1cc(C)ncc1)=O)n2)=O CODIMGJCYJUGOB-XMMPIXPASA-N 0.000 description 1
- HYQPADRMGXDUSF-RGFWRHHQSA-N CCN(CC1)CCC1[U]c1c2[n]([C@H](CCCC3)CN3C(C=C)=[U])c(NC(c3ccnc(C)c3)=N)nc2ccc1 Chemical compound CCN(CC1)CCC1[U]c1c2[n]([C@H](CCCC3)CN3C(C=C)=[U])c(NC(c3ccnc(C)c3)=N)nc2ccc1 HYQPADRMGXDUSF-RGFWRHHQSA-N 0.000 description 1
- LVILGAOSPDLNRM-UHFFFAOYSA-N Cc1ccncn1 Chemical compound Cc1ccncn1 LVILGAOSPDLNRM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968225P | 2014-03-20 | 2014-03-20 | |
| US61/968,225 | 2014-03-20 | ||
| PCT/US2015/021455 WO2015143148A1 (en) | 2014-03-20 | 2015-03-19 | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019151001A Division JP7073316B2 (ja) | 2014-03-20 | 2019-08-21 | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017512833A JP2017512833A (ja) | 2017-05-25 |
| JP2017512833A5 true JP2017512833A5 (enExample) | 2018-05-17 |
| JP6577012B2 JP6577012B2 (ja) | 2019-09-18 |
Family
ID=52997514
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017501110A Active JP6577012B2 (ja) | 2014-03-20 | 2015-03-19 | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
| JP2019151001A Active JP7073316B2 (ja) | 2014-03-20 | 2019-08-21 | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
| JP2022078150A Active JP7394168B2 (ja) | 2014-03-20 | 2022-05-11 | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019151001A Active JP7073316B2 (ja) | 2014-03-20 | 2019-08-21 | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
| JP2022078150A Active JP7394168B2 (ja) | 2014-03-20 | 2022-05-11 | 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10005765B2 (enExample) |
| EP (2) | EP3119762B9 (enExample) |
| JP (3) | JP6577012B2 (enExample) |
| KR (3) | KR102416358B1 (enExample) |
| CN (3) | CN106536506A (enExample) |
| AU (1) | AU2015231202B9 (enExample) |
| CA (2) | CA3175724C (enExample) |
| DK (1) | DK3119762T3 (enExample) |
| ES (1) | ES2891734T3 (enExample) |
| IL (3) | IL291000B2 (enExample) |
| MX (2) | MX377384B (enExample) |
| PT (1) | PT3119762T (enExample) |
| RU (2) | RU2021101430A (enExample) |
| SG (1) | SG11201607706SA (enExample) |
| TW (2) | TWI683813B (enExample) |
| WO (1) | WO2015143148A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9227978B2 (en) | 2013-03-15 | 2016-01-05 | Araxes Pharma Llc | Covalent inhibitors of Kras G12C |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| KR102409739B1 (ko) | 2014-03-20 | 2022-06-17 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| EP3119762B9 (en) | 2014-03-20 | 2021-10-20 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2898765T3 (es) | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| ES2856880T3 (es) | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| WO2017069822A2 (en) | 2015-07-20 | 2017-04-27 | The Brigham And Women's Hospital, Inc. | Shear-thinning compositions as an intravascular embolic agent |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
| EP3356347A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10689356B2 (en) | 2015-09-28 | 2020-06-23 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10730867B2 (en) | 2015-09-28 | 2020-08-04 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058792A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10975071B2 (en) | 2015-09-28 | 2021-04-13 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10414757B2 (en) | 2015-11-16 | 2019-09-17 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| WO2018064510A1 (en) | 2016-09-29 | 2018-04-05 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| EP3573971A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer |
| WO2018140599A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Benzothiophene and benzothiazole compounds and methods of use thereof |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| US11136308B2 (en) | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| CN110869357A (zh) | 2017-05-25 | 2020-03-06 | 亚瑞克西斯制药公司 | 化合物及其用于治疗癌症的使用方法 |
| JP7313364B2 (ja) * | 2018-02-21 | 2023-07-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体 |
| CN108191861B (zh) * | 2018-03-01 | 2020-10-02 | 天津大学 | N-[5-(嘧啶-2-氨基)-2,4-二取代苯基]-反式-2,4-戊二烯酰胺 |
| CA3107168A1 (en) | 2018-08-01 | 2020-02-06 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| IL281344B2 (en) | 2018-09-10 | 2025-09-01 | Mirati Therapeutics Inc | Combination of adagrasib and cetuximab for cancer treatment |
| CN111747950B (zh) | 2019-03-29 | 2024-01-23 | 深圳福沃药业有限公司 | 用于治疗癌症的嘧啶衍生物 |
| JP7590996B2 (ja) | 2019-06-24 | 2024-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｅｇｆｒ阻害剤としての新たな大環状化合物および誘導体 |
| EP4225309A4 (en) * | 2020-10-12 | 2024-12-25 | Dana-Farber Cancer Institute, Inc. | COVALENT INHIBITORS OF EGFR AND METHODS OF USE THEREOF |
| EP4237423B1 (en) | 2020-11-02 | 2024-12-11 | Boehringer Ingelheim International GmbH | Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors |
| CN114057771B (zh) * | 2020-12-03 | 2023-10-03 | 北京鞍石生物科技有限责任公司 | 大环化合物及其制备方法和应用 |
| EP4572754A1 (en) | 2022-08-15 | 2025-06-25 | Nalo Therapeutics, Inc. | N-(1-((r)-1-acryloylazepan-3-yl)-7-chloro-6-(((r)-tetrahydrofuran-3-yl)oxy)-1h-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (nx-019) for use in the treatment of egfr mutant cancer |
| WO2025175145A1 (en) | 2024-02-14 | 2025-08-21 | Nalo Therapeutics, Inc. | N-(1-((r)-1-acryloylazepan-3-yl)-7-chloro-6-(((r)-tetrahydrofuran-3-yl)oxy)-1h-b enzo[d]imidazol-2-yl)-2-methylisonicotinamide (nx-019) for use in the treatment of egfr mutant cancer |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| ES8702440A1 (es) | 1984-10-04 | 1986-12-16 | Monsanto Co | Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa. |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| WO1997001331A2 (en) | 1995-06-27 | 1997-01-16 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| US6375987B1 (en) | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
| AU722289B2 (en) | 1996-10-01 | 2000-07-27 | Aptalis Pharmatech, Inc. | Taste-masked microcapsule compositions and methods of manufacture |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| DE19648576C2 (de) | 1996-11-23 | 1999-08-12 | Lohmann Therapie Syst Lts | Lutschtablette zur modifizierten Freisetzung von Wirkstoffen im Gastrointestinaltrakt |
| DE69719367T2 (de) | 1996-12-20 | 2003-10-16 | Takeda Chemical Industries, Ltd. | Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US7169410B1 (en) | 1998-05-19 | 2007-01-30 | Sdg, Inc. | Targeted liposomal drug delivery system |
| MA26659A1 (fr) * | 1998-08-06 | 2004-12-20 | Pfizer | Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation. |
| DK1126826T6 (en) | 1998-11-02 | 2019-06-24 | Alkermes Pharma Ireland Ltd | Multiparticulate modified release of methylphenidate |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| ATE396978T1 (de) * | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| US6623756B1 (en) | 2000-04-27 | 2003-09-23 | Noveon Ip Holdings Corp. | Directly compressed solid dosage articles |
| MXPA03001771A (es) | 2000-08-30 | 2003-06-04 | Pfizer Prod Inc | Formulaciones de liberacion sostenida para secretagogos de hormona del crecimiento. |
| ES2351249T3 (es) | 2001-07-27 | 2011-02-02 | Astellas Pharma Inc. | Composición que comprende partículas finas, de liberación sostenida, para comprimidos de disgregación rápida en la cavidad bucal. |
| WO2003026626A2 (en) | 2001-09-28 | 2003-04-03 | Mcneil-Ppc, Inc. | Modified release dosage forms |
| ES2367422T3 (es) | 2001-10-09 | 2011-11-03 | Amgen Inc. | Derivados de imidazol como agentes antiinflamatorios. |
| ES2233876T3 (es) | 2001-12-19 | 2005-06-16 | Astrazeneca Ab | Nuevo recubrimiento de pelicula que contiene un copolimero acrilato de etilo/metacrilato de metilo y poli (acetato de vinilo). |
| US6958161B2 (en) | 2002-04-12 | 2005-10-25 | F H Faulding & Co Limited | Modified release coated drug preparation |
| US7485322B2 (en) | 2002-12-24 | 2009-02-03 | Lek Pharmaceuticals D.D. | Modified release pharmaceutical composition |
| US7427414B2 (en) | 2006-01-18 | 2008-09-23 | Astron Research Limited | Modified release oral dosage form using co-polymer of polyvinyl acetate |
| CN101631779A (zh) * | 2006-12-12 | 2010-01-20 | 先灵公司 | 含有三环系统的天冬氨酰蛋白酶抑制剂 |
| WO2009061596A1 (en) * | 2007-11-09 | 2009-05-14 | Schering Corporation | Compounds for inhibiting ksp kinesin activity |
| EP2265270A1 (en) | 2008-02-04 | 2010-12-29 | OSI Pharmaceuticals, Inc. | 2-aminopyridine kinase inhibitors |
| FR2952552B1 (fr) * | 2009-11-19 | 2012-01-13 | Commissariat Energie Atomique | Dispositif de recuperation de nanopoudres et de poudres ultrafines contenues dans un gaz |
| US8461328B2 (en) | 2010-01-12 | 2013-06-11 | Genentech, Inc. | Tricyclic heterocyclic compounds, compositions and methods of use thereof |
| WO2011099832A2 (en) | 2010-02-12 | 2011-08-18 | Crystalgenomics, Inc. | Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same |
| KR20130108543A (ko) | 2010-08-05 | 2013-10-04 | 암젠 인코포레이션 | 역형성 림프종 키나제를 억제하는 벤즈이미다졸 및 아자벤즈이미다졸 화합물 |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| EP2779833A4 (en) | 2011-11-14 | 2015-03-18 | Tesaro Inc | MODULATION OF SPECIFIC TYROSINE KINASES |
| JP2015516439A (ja) | 2012-05-10 | 2015-06-11 | シンタ ファーマシューティカルズ コーポレーション | Ｈｓｐ９０阻害化合物で癌を治療すること |
| US20150152083A1 (en) * | 2012-06-06 | 2015-06-04 | Irm Llc, A Delaware Limited Liability Company | Compounds and Compositions for Modulating EGFR Activity |
| JO3300B1 (ar) * | 2012-06-06 | 2018-09-16 | Novartis Ag | مركبات وتركيبات لتعديل نشاط egfr |
| US9550737B2 (en) | 2012-06-11 | 2017-01-24 | Ucb Biopharma Sprl | TNF -α modulating benzimidazoles |
| KR102155559B1 (ko) | 2012-06-27 | 2020-09-15 | 4에스체 악티엔게젤샤프트 | 암, 자가면역성 염증 및 중추신경계 장애를 치료하기 위한 비플루오로디옥살란-아미노-벤즈이미다졸 키나제 억제제 |
| US9573958B2 (en) * | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| US9932329B2 (en) | 2014-03-03 | 2018-04-03 | Principia Biopharma, Inc. | Benzimidazole derivatives as RLK and ITK inhibitors |
| EP3119762B9 (en) * | 2014-03-20 | 2021-10-20 | Capella Therapeutics, Inc. | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer |
| KR102409739B1 (ko) | 2014-03-20 | 2022-06-17 | 카펠라 테라퓨틱스, 인크. | 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체 |
| CN104447765A (zh) | 2014-12-31 | 2015-03-25 | 深圳铂立健医药有限公司 | 三环化合物及其药物组合物和应用 |
| US10057707B2 (en) | 2015-02-03 | 2018-08-21 | Dolby Laboratories Licensing Corporation | Optimized virtual scene layout for spatial meeting playback |
| US10590108B2 (en) | 2015-09-23 | 2020-03-17 | Capella Therapeutics, Inc. | Benzimidazoles for use in the treatment of cancer and inflammatory diseases |
-
2015
- 2015-03-19 EP EP15717994.6A patent/EP3119762B9/en active Active
- 2015-03-19 US US15/126,997 patent/US10005765B2/en active Active
- 2015-03-19 ES ES15717994T patent/ES2891734T3/es active Active
- 2015-03-19 RU RU2021101430A patent/RU2021101430A/ru unknown
- 2015-03-19 TW TW104108911A patent/TWI683813B/zh active
- 2015-03-19 PT PT157179946T patent/PT3119762T/pt unknown
- 2015-03-19 CA CA3175724A patent/CA3175724C/en active Active
- 2015-03-19 KR KR1020167028920A patent/KR102416358B1/ko active Active
- 2015-03-19 WO PCT/US2015/021455 patent/WO2015143148A1/en not_active Ceased
- 2015-03-19 CA CA2943220A patent/CA2943220C/en active Active
- 2015-03-19 AU AU2015231202A patent/AU2015231202B9/en active Active
- 2015-03-19 RU RU2016141052A patent/RU2741914C2/ru active
- 2015-03-19 IL IL291000A patent/IL291000B2/en unknown
- 2015-03-19 MX MX2016012097A patent/MX377384B/es active IP Right Grant
- 2015-03-19 EP EP21173958.6A patent/EP3922630A1/en active Pending
- 2015-03-19 KR KR1020227022282A patent/KR102663309B1/ko active Active
- 2015-03-19 KR KR1020247014448A patent/KR20240064750A/ko active Pending
- 2015-03-19 CN CN201580023803.1A patent/CN106536506A/zh active Pending
- 2015-03-19 DK DK15717994.6T patent/DK3119762T3/da active
- 2015-03-19 CN CN202210345286.1A patent/CN114940673B/zh active Active
- 2015-03-19 CN CN202210345304.6A patent/CN114989140B/zh active Active
- 2015-03-19 SG SG11201607706SA patent/SG11201607706SA/en unknown
- 2015-03-19 TW TW108147560A patent/TWI807150B/zh active
- 2015-03-19 JP JP2017501110A patent/JP6577012B2/ja active Active
-
2016
- 2016-09-15 IL IL247852A patent/IL247852B/en active IP Right Grant
- 2016-09-19 MX MX2020012165A patent/MX2020012165A/es unknown
-
2018
- 2018-06-11 US US16/005,490 patent/US10647707B2/en active Active
-
2019
- 2019-08-21 JP JP2019151001A patent/JP7073316B2/ja active Active
-
2020
- 2020-05-05 US US16/867,451 patent/US11787788B2/en active Active
-
2021
- 2021-04-26 IL IL282651A patent/IL282651B/en unknown
-
2022
- 2022-05-11 JP JP2022078150A patent/JP7394168B2/ja active Active
-
2024
- 2024-04-12 US US18/634,747 patent/US20250092028A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512833A5 (enExample) | ||
| JP2017508816A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2016510323A5 (enExample) | ||
| JP2014509647A5 (enExample) | ||
| JP2017537940A5 (enExample) | ||
| JP2017530959A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2017511815A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2019514874A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| SI2743266T1 (en) | Protein kinase inhibitors (variants), their use in the treatment of oncological diseases and the pharmaceutical composition on their basis | |
| JP2013528182A5 (enExample) | ||
| JP2013507448A5 (enExample) | ||
| JP2017537937A5 (enExample) | ||
| JP2010280669A5 (enExample) | ||
| JP2013530238A5 (enExample) | ||
| JP2013533884A5 (enExample) | ||
| JP2016506962A5 (enExample) | ||
| JP2013533883A5 (enExample) | ||
| JP2016528273A5 (enExample) | ||
| JP2021508318A5 (enExample) | ||
| JP2015528812A5 (enExample) | ||
| JP2017506666A5 (enExample) |